KR20180064222A - Manufacturing method of husked barley granules - Google Patents
Manufacturing method of husked barley granules Download PDFInfo
- Publication number
- KR20180064222A KR20180064222A KR1020160164609A KR20160164609A KR20180064222A KR 20180064222 A KR20180064222 A KR 20180064222A KR 1020160164609 A KR1020160164609 A KR 1020160164609A KR 20160164609 A KR20160164609 A KR 20160164609A KR 20180064222 A KR20180064222 A KR 20180064222A
- Authority
- KR
- South Korea
- Prior art keywords
- rhizome
- lactic acid
- acid bacteria
- fruit
- enzyme
- Prior art date
Links
- 239000008187 granular material Substances 0.000 title claims abstract description 49
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 31
- 235000007340 Hordeum vulgare Nutrition 0.000 title abstract description 26
- 240000005979 Hordeum vulgare Species 0.000 title 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 68
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 34
- 239000004310 lactic acid Substances 0.000 claims abstract description 34
- 241000894006 Bacteria Species 0.000 claims abstract description 31
- 238000000034 method Methods 0.000 claims abstract description 30
- 239000012141 concentrate Substances 0.000 claims abstract description 20
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 11
- 238000005507 spraying Methods 0.000 claims abstract description 10
- 239000012530 fluid Substances 0.000 claims abstract description 8
- 235000013311 vegetables Nutrition 0.000 claims abstract description 8
- 102000004190 Enzymes Human genes 0.000 claims description 32
- 108090000790 Enzymes Proteins 0.000 claims description 32
- 229940088598 enzyme Drugs 0.000 claims description 32
- 235000020971 citrus fruits Nutrition 0.000 claims description 29
- 241000207199 Citrus Species 0.000 claims description 26
- 240000007124 Brassica oleracea Species 0.000 claims description 22
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 claims description 22
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 claims description 22
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 claims description 22
- 235000017647 Brassica oleracea var italica Nutrition 0.000 claims description 22
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 claims description 22
- 240000003259 Brassica oleracea var. botrytis Species 0.000 claims description 22
- 244000000626 Daucus carota Species 0.000 claims description 21
- 235000002767 Daucus carota Nutrition 0.000 claims description 21
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 15
- 238000000855 fermentation Methods 0.000 claims description 13
- 230000004151 fermentation Effects 0.000 claims description 13
- 239000003963 antioxidant agent Substances 0.000 claims description 12
- 230000003078 antioxidant effect Effects 0.000 claims description 12
- 235000007164 Oryza sativa Nutrition 0.000 claims description 11
- 235000009566 rice Nutrition 0.000 claims description 11
- 230000035784 germination Effects 0.000 claims description 10
- 210000002421 cell wall Anatomy 0.000 claims description 9
- 235000012055 fruits and vegetables Nutrition 0.000 claims description 9
- 230000000593 degrading effect Effects 0.000 claims description 7
- 230000001093 anti-cancer Effects 0.000 claims description 6
- 230000003178 anti-diabetic effect Effects 0.000 claims description 6
- 239000003472 antidiabetic agent Substances 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 108010059820 Polygalacturonase Proteins 0.000 claims description 5
- 230000032683 aging Effects 0.000 claims description 5
- 108010093305 exopolygalacturonase Proteins 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 206010011469 Crying Diseases 0.000 claims description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 4
- 101710130006 Beta-glucanase Proteins 0.000 claims description 3
- 108010059892 Cellulase Proteins 0.000 claims description 3
- 101710121765 Endo-1,4-beta-xylanase Proteins 0.000 claims description 3
- 229940106157 cellulase Drugs 0.000 claims description 3
- 235000013376 functional food Nutrition 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 3
- 229940059442 hemicellulase Drugs 0.000 claims description 3
- 108010002430 hemicellulase Proteins 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 2
- 230000002255 enzymatic effect Effects 0.000 claims description 2
- QNRATNLHPGXHMA-XZHTYLCXSA-N (r)-(6-ethoxyquinolin-4-yl)-[(2s,4s,5r)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]methanol;hydrochloride Chemical compound Cl.C([C@H]([C@H](C1)CC)C2)CN1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OCC)C=C21 QNRATNLHPGXHMA-XZHTYLCXSA-N 0.000 claims 1
- 240000007594 Oryza sativa Species 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 238000000227 grinding Methods 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 241000209219 Hordeum Species 0.000 abstract description 26
- 235000015097 nutrients Nutrition 0.000 abstract description 5
- 230000006378 damage Effects 0.000 abstract description 3
- 238000005469 granulation Methods 0.000 abstract description 3
- 230000003179 granulation Effects 0.000 abstract description 3
- 238000001035 drying Methods 0.000 abstract description 2
- 239000007921 spray Substances 0.000 abstract description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 53
- 239000000284 extract Substances 0.000 description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 22
- 230000000694 effects Effects 0.000 description 21
- 239000000469 ethanolic extract Substances 0.000 description 18
- 230000002401 inhibitory effect Effects 0.000 description 16
- 235000008504 concentrate Nutrition 0.000 description 15
- 238000000605 extraction Methods 0.000 description 13
- 241000209094 Oryza Species 0.000 description 11
- 235000006708 antioxidants Nutrition 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 10
- 235000013824 polyphenols Nutrition 0.000 description 10
- 230000004083 survival effect Effects 0.000 description 10
- 239000000796 flavoring agent Substances 0.000 description 9
- 235000019634 flavors Nutrition 0.000 description 9
- 150000008442 polyphenolic compounds Chemical class 0.000 description 9
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 8
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 8
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 8
- 230000003833 cell viability Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 108010093894 Xanthine oxidase Proteins 0.000 description 7
- 102100033220 Xanthine oxidase Human genes 0.000 description 7
- 230000003276 anti-hypertensive effect Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000003013 cytotoxicity Effects 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 229930003935 flavonoid Natural products 0.000 description 6
- 150000002215 flavonoids Chemical class 0.000 description 6
- 235000017173 flavonoids Nutrition 0.000 description 6
- 230000001953 sensory effect Effects 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 230000002292 Radical scavenging effect Effects 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 4
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
- 102000005862 Angiotensin II Human genes 0.000 description 4
- 101800000733 Angiotensin-2 Proteins 0.000 description 4
- 235000021559 Fruit Juice Concentrate Nutrition 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- 229950006323 angiotensin ii Drugs 0.000 description 4
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 235000011511 Diospyros Nutrition 0.000 description 3
- 244000236655 Diospyros kaki Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 201000005569 Gout Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 3
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 3
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 3
- 229960003459 allopurinol Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000007760 free radical scavenging Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 229940116269 uric acid Drugs 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- 239000004382 Amylase Substances 0.000 description 2
- 108010065511 Amylases Proteins 0.000 description 2
- 102000013142 Amylases Human genes 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 229920002488 Hemicellulose Polymers 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930003270 Vitamin B Natural products 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 102000016679 alpha-Glucosidases Human genes 0.000 description 2
- 108010028144 alpha-Glucosidases Proteins 0.000 description 2
- 235000019418 amylase Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- -1 antihypertensive Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 235000021329 brown rice Nutrition 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000002657 fibrous material Substances 0.000 description 2
- 229940074391 gallic acid Drugs 0.000 description 2
- 235000004515 gallic acid Nutrition 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- CNNRPFQICPFDPO-UHFFFAOYSA-N octacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCO CNNRPFQICPFDPO-UHFFFAOYSA-N 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 238000004073 vulcanization Methods 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- 229960002666 1-octacosanol Drugs 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010050661 Platelet aggregation inhibition Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003627 anti-cholesterol Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229940069780 barley extract Drugs 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 1
- 229960002529 benzbromarone Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000008242 dietary patterns Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 210000001981 hip bone Anatomy 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 235000020995 raw meat Nutrition 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000007103 stamina Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/152—Cereal germ products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/104—Fermentation of farinaceous cereal or cereal material; Addition of enzymes or microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/22—Agglomeration or granulation with pulverisation of solid particles, e.g. in a free-falling curtain
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
Abstract
Description
본 발명은 포도당, 과당 등의 유리당과 여러 종류의 아미노산을 증폭시켜 식미와 영양을 상당한 수준으로 개선되었으며, 항산화, 항고혈압 및 항염증의 기능성이 향상된 현맥 과립의 제조방법에 관한 것이다.The present invention relates to a method for producing a rhizome granule which is improved in taste and nutrition to a considerable level by amplifying free sugars such as glucose and fructose and various kinds of amino acids and has improved antioxidant, antihypertensive and anti-inflammatory functions.
보리는 가을에 파종을 하고 대체적으로 병충해가 적은 저온기인 가을과 봄 계절에 생육이 진행됨으로 다른 작물에 비해 병충해가 심하지 않아 농약을 거의 사용하지 않고도 친환경 유기재배가 가능한 작물이므로 무공해 식품이라고 해도 과언이 아니다. Barley is sown in autumn and generally grows in autumn and spring, which is a low-temperature season with few pests and diseases. Therefore, it is not pollution-free compared to other crops and is an environmentally friendly organic cultivation without the use of pesticides. no.
보리의 효능을 살펴보면 칼슘, 섬유질, 비타민 B군 등이 다른 곡물보다 훨씬 많이 함유하고 있는 것으로 알려져 있는데, 보리가 함유하고 있는 섬유소 성분은 혈중 콜레스테롤 농도를 감소시켜 각종 성인병의 예방 및 치료는 물론 장(腸)의 기능 향상과 특히 변비해소에 효능이 있는 것으로 알려져 있고, 보리가 함유하고 있는 비타민 B군의 성분은 위와 장의 점막을 튼튼히 해주는 한편 부신피질호르몬의 합성과 조절로 피로회복, 스트레스 해소에 효능이 있는 것으로 전해지고 있으며, 보리가 함유하고 있는 칼슘 성분은 뼈와 치아를 튼튼하게 하여 골절이나 충치 예방에 큰 도움이 되는 것으로 잘 알려져 있다. 또한, 피부를 탄력 있게 해주고, 혈압이 정상을 유지토록 도와주며, 심장질환 예방 및 지방 축적을 억제하여 비만을 예방하고, 고혈압, 뇌졸증, 당뇨병을 예방하며, 스테미너 증진과 더불어 스트레스 저항력을 향상시키는 효능이 있다.The effect of barley is known to contain much more calcium, fiber and vitamin B than other grains. The fiber content of barley reduces the blood cholesterol concentration, thus preventing and treating various diseases, Intestinal) and especially the effect of clearing constipation is known to be effective, and the ingredients of the vitamin B group contains barley stomach and intestinal mucosa, while strengthening the synthesis and regulation of corticosteroids to relieve fatigue, stress relieving efficacy , And the calcium content of the barley makes it stronger for bones and teeth, and is well known for its great help in preventing fractures and cavities. It also helps to maintain skin's elasticity, maintain blood pressure, prevent heart disease and prevent fat accumulation, prevent obesity, prevent hypertension, stroke, diabetes, and improve stamina and stress resistance. .
보리에는 이외에도 인체의 생리대사에 필요한 비타민과 무기질을 다량으로 함유하고 있으면서도 상대적으로 열량은 높지 않은 것으로 알려져 있어, 최근 국민 소득수준 향상과 더불어 국민들의 식생활 패턴이 다양화되면서 현대인들에게는 건강식품, 웰빙식품, 다이어트식품으로 각광을 받고 있다.Barley is known to contain a large amount of vitamins and minerals as well as a relatively high calorie content for the human body's physiological enzymes. Recently, as people's dietary patterns have been diversified with the improvement of the national income level, Food, and diet foods.
자연상태의 보리는 거친 겉껍질과 소수성(疏水性)이 강한 왁스층인 내피로 싸여져 있어 자연 그대로의 보리를 식용으로 직접 사용할 수는 없고, 일반적으로 압맥(납작보리, 도정한 보리이용), 보리가루, 보리빵, 보리추출음료 등 다양한 형태로 가공되어 식용으로 이용되고 있다. 그러나 보리가 함유하고 있는 인체에 유익한 성분들을 온전히 섭취하기 위해서는 현미와 같이 배아와 내피가 그대로 보존된 현맥(玄麥, 쌀보리)을 그대로 섭취하는 것이 가장 이상적이다. Natural barley is wrapped with a rough surface and a hydrophobic wax layer. It is not possible to use natural barley directly for edible purposes. Generally, barley is used as a paddy barley (used for barley), barley powder , Barley bread, barley extract beverage, etc., and it is used for food. However, in order to consume the ingredients beneficial to the human body contained in barley, it is ideal to consume the raw meat (玄 麦, barley barley) as it is, such as brown rice, in which the embryo and endothelium are preserved intact.
이러한 이유로 보리의 장점을 살려 영양소가 파괴되지 않고, 식감과 풍미가 개선되며, 유용성분을 다양한 방법으로 섭취할 수 있는 방법의 개발이 요구되고 있다. 과립은 유통기한이 길고 보관이 간편하며, 섭취가 용이하다는 장점이 있으나 현맥을 원료로 한 과립은 식감이 거칠고 풍미가 부족한 단점이 있다. 이에 본 발명자는 인체에 유용한 성분들을 온전히 함유하고 있는 현맥을 이용하여 영양소가 파괴되지 않고, 식감과 풍미가 개선되며, 항산화, 항염, 항고혈압 활성을 나타내는 현맥 과립을 제조하여 본 발명을 완성하게 되었다. For this reason, there is a need to develop a method that can utilize the advantages of barley so that the nutrients are not destroyed, the texture and flavor are improved, and the useful components are ingested in various ways. Granules have the advantage of long shelf life, easy storage and easy ingestion, but the granules made from the rhizomes have rough texture and lack flavor. Accordingly, the present inventors have completed the present invention by producing a rhizome granule which does not destroy nutrients, improves the texture and flavor, and exhibits antioxidant, anti-inflammatory and antihypertensive activity by using a rhythm containing the components useful for the human body .
본 발명의 목적은 영양소 파괴가 감소되고, 인체에 유익한 성분이 증가할 뿐만 아니라 거친식감을 개선되고, 풍미가 향상되어 소비자 기호도를 향상시킨 현맥 과립의 제조방법을 제공하는 데 있다. It is an object of the present invention to provide a method of manufacturing a rhizome granule which has reduced nutrient destruction, increases components beneficial to the human body, improves rough texture, and improves flavor, thereby improving consumer preference.
또한, 본 발명의 다른 목적은 상기 제조방법에 의해 제조된 현맥 과립을 제공하는 데 있다.It is another object of the present invention to provide a rhizome granule produced by the above production method.
또한, 본 발명의 다른 목적은 상기 제조방법에 의해 제조된 현맥 과립을 유효성분으로 포함하는 항산화, 항고열압, 항당뇨, 항염증 또는 항암활성용 건강기능식품을 제공하는데 있다. Another object of the present invention is to provide a health functional food for antioxidant, anti-hyperthermia, anti-diabetic, anti-inflammatory or anticancer activity comprising rhizome granules prepared by the above-mentioned method.
상기한 목적을 달성하기 위하여 본 발명은 (a) 도정하지 않은 현맥을 발아시키는 단계; (b) 상기 발아된 현맥을 덱스트린화하는 단계; (c) 진공 상에서 상기 덱스트린화된 현맥을 유산균으로 발효시키는 단계; (d) 상기 유산균으로 발효된 현맥을 분말화하는 단계; 및 (e) 상기 분말화된 현맥에 과채 농축액을 스프레이 형태로 분사하면서 유동층 건조(fluid bed crying) 방식으로 과립을 생성시키는 단계;를 포함하는 현맥 과립 제조방법을 제공한다. In order to accomplish the above object, the present invention provides a method of manufacturing a glaze comprising the steps of: (a) germinating a rhizome; (b) dextrinizing the germinated rhizome; (c) fermenting said dextrinized rhizome with lactic acid bacteria on a vacuum; (d) pulverizing the rhizome fermented with the lactic acid bacteria; And (e) forming granules by a fluid bed crying method while spraying the concentrate of the fruit and vegetable juice in the powdered rhombus.
상기 (a) 단계는 현맥 100 중량% 중에서 85 내지 90 중량%만을 발아시키는 것일 수 있다. The step (a) may be a step of germinating only 85 to 90% by weight of 100% by weight of rhizome.
상기 (a) 단계는 발아된 현맥 유근의 시원체인 백체의 길이가 0.05 이상 내지 1 mm 미만일 수 있다. In the step (a), the length of the bag, which is a germinated rootstock root, may be 0.05 to less than 1 mm.
상기 (b) 단계는 덱스트린화 하기 전에 발아 현맥을 춘화처리하는 단계를 더 포함하는 것일 수 있다. The step (b) may further include a step of subjecting the germination pulse to a vernalization process before the dextrinization.
상기 (c) 단계는 현맥 10 중량부에 대하여 미강 3 내지 15 중량부를 혼합하여 유산균으로 발효시키는 것일 수 있다. In the step (c), 3 to 15 parts by weight of rice bran may be mixed with 10 parts by weight of the row of beans, followed by fermentation with lactic acid bacteria.
상기 과채 농축액은 과일 또는 채소를 착즙하여 농축한 농축액; 또는 과일 또는 채소를 세포벽 분해효소로 효소처리한 후 착즙하여 농축한 농축액인 것일 수 있으며, 상기 과채는 감귤, 브로콜리, 양배추 및 당근 중에서 선택되는 것일 수 있다. Wherein the fruit and vegetable concentrate is a concentrated fruit and vegetable concentrate; Or a concentrate obtained by enzymatically treating fruits or vegetables with cell wall degrading enzymes and then concentrating them by juice, and the fruit can be selected from citrus fruits, broccoli, cabbage and carrots.
상기 (d) 단계는 분말화하기 전에 유산균으로 발효된 현맥에 과채 효소분해물을 분사한 뒤 1 내지 6시간 동안 숙성시키는 단계를 더 포함하는 것일 수 있다. The step (d) may further include a step of spraying the enzyme hydrolyzate to fermented fermented lactic acid bacteria before pulverization and aging for 1 to 6 hours.
상기 과채 효소분해물은 감귤, 브로콜리, 양배추 및 당근 중에서 선택되는 과채를 베타-글루카나아제(β-glucanase), 헤미셀룰라아제(hemicellulase), 셀룰라아제(cellulase), 자일란나아제(xylanase), 펙티나아제(pectinase) 및 아라비나아제(arabinase) 중에서 선택되는 1종 또는 2종 이상의 세포벽 분해효소로 효소분해한 다음 효소를 실활시키고, 착즙하여 제조된 것일 수 있다. The enzyme hydrolyzate of the present invention is an enzyme hydrolyzate selected from the group consisting of citrus, broccoli, cabbage and carrots as beta-glucanase, hemicellulase, cellulase, xylanase and pectinase pectinase and arabinase, followed by inactivating the enzyme, and then adding the solution to the solution.
또한, 상기한 다른 목적을 달성하기 위한 본 발명의 현맥 과립은 상기 제조방법에 의해 제조될 수 있다.In order to achieve the above-mentioned other objects, the rhombus granule of the present invention can be manufactured by the above-mentioned manufacturing method.
또한, 본 발명에 따른 현맥 과립은 항산화, 항고열압, 항당뇨, 항염증 또는 항암 활성의 기능성을 나타내므로, 항산화, 항고열압, 항당뇨, 항염증 또는 항암용 건강기능식품으로 이용될 수 있다.In addition, the rhizome granules according to the present invention exhibit antioxidant, anti-hypertension, anti-diabetic, anti-inflammatory or anticancer activity functions and thus can be used as antioxidant, anti-hypertension, antidiabetic, anti- have.
본 발명의 현맥을 이용한 과립은 도정하지 않은 현맥을 이용하므로 인체에 인체에 유익한 성분들을 온전히 함유하고 있는데, 이러한 현맥을 덱스트린화 및 유산균으로 발효시키고, 과채 농축액을 첨가하여 과립을 형성시킴으로써 현맥 특유의 식미와 거친 식감을 상당수준 개선하였다. Since the granule using the rhizome of the present invention utilizes a rhizome that is unshakable, it completely contains the components beneficial to the human body. The rhizome is fermented by dextrinization and lactic acid bacteria, and the granule is formed by adding the fruit juice concentrate, And improved the texture and rough texture significantly.
현맥의 외피층은 경질(硬質)의 섬유질(해미세루로이즈) 및 소수성의 왁스층으로 형성이 되어있어 과립형성 시 거친식감의 개선이 어렵지만, 본 발명과 같이 덱스트린 처리로 외피를 유연화시키면 소수성의 외피가 친수성의 외피로 전환시킴으로서 유산균으로의 발효를 용이하게 하여 유익한 성분의 함량을 더욱 향상시켰을 뿐만 아니라, 과채 농축액을 활용한 미립공정을 통해 과립을 제조함으로써 거친 식감을 개선하고 풍미가 향상되었다. 특히, 본 발명에 따른 현맥 과립은 항산화, 항고혈압, 항당뇨, 항염증 및 항암 등에 활성을 나타내므로, 항산화, 항고혈압, 항당뇨, 항염증 또는 항암 활성을 위한 건강기능식품으로 유용하다. Since the outer shell layer of the rhombus is formed of a hard fibrous material (hemicellulose) and a hydrophobic wax layer, it is difficult to improve rough texture during granule formation. However, when the outer skin is softened by dextrin treatment as in the present invention, To facilitate the fermentation into lactic acid bacteria, thereby further improving the content of the beneficial ingredient. In addition, the granulated product was improved in the granulation process by using the fruit juice concentrate to improve the rough texture and the flavor. In particular, the rhizome granules according to the present invention are useful as a health functional food for antioxidant, antihypertensive, anti-diabetic, anti-inflammatory or anticancer activity since they exhibit antioxidant, antihypertensive, antidiabetic, anti-inflammatory and anti-cancer activity.
도 1은 본 발명의 일 실시예에 따른 감귤이 첨가된 현맥 과립의 항염 활성을 평가한 도이다.
도 2는 본 발명의 일 실시예에 따른 브로콜리가 첨가된 현맥 과립의 항염 활성을 평가한 도이다.
도 3은 본 발명의 일 실시예에 따른 양배추가 첨가된 현맥 과립의 항염 활성을 평가한 도이다.
도 4는 본 발명의 일 실시예에 따른 당근이 첨가된 현맥 과립의 항염 활성을 평가한 도이다. FIG. 1 is a graph showing the anti-inflammatory activity of citrus-added rhizome granules according to an embodiment of the present invention.
FIG. 2 is a graph showing an anti-inflammatory activity of broccoli-added rhizome granules according to an embodiment of the present invention. FIG.
FIG. 3 is a graph showing an anti-inflammatory activity of cabbage-added rhizome granules according to an embodiment of the present invention.
FIG. 4 is a graph showing an anti-inflammatory activity of carnauba-added rhizome granules according to an embodiment of the present invention.
본 발명은 포도당, 과당 등의 유리당과 여러 종류의 아미노산을 증폭시켜 식미와 영양을 상당한 수준으로 개선되었으며, 항산화, 항고혈압 및 항염증의 기능성이 향상된 현맥 과립의 제조방법에 관한 것이다.
The present invention relates to a method for producing a rhizome granule which is improved in taste and nutrition to a considerable level by amplifying free sugars such as glucose and fructose and various kinds of amino acids and has improved antioxidant, antihypertensive and anti-inflammatory functions.
이하, 본 발명을 상세하게 설명한다. Hereinafter, the present invention will be described in detail.
본 발명의 현맥 과립 제조방법은 (a) 도정하지 않은 현맥을 발아시키는 단계; (b) 상기 발아된 현맥을 덱스트린화하는 단계; (c) 진공 상에서 상기 덱스트린화된 현맥을 유산균으로 발효시키는 단계; (d) 상기 유산균으로 발효된 현맥을 분말화하는 단계; 및 (e) 상기 분말화된 현맥에 과채 농축액을 스프레이 형태로 분사하면서 유동층 건조(fluid bed crying) 방식으로 과립을 생성시키는 단계;를 포함한다. The method of manufacturing a hip bone granule of the present invention comprises the steps of: (a) germinating an uncooked stem; (b) dextrinizing the germinated rhizome; (c) fermenting said dextrinized rhizome with lactic acid bacteria on a vacuum; (d) pulverizing the rhizome fermented with the lactic acid bacteria; And (e) forming a granule by fluid bed crying while spraying the concentrate of the fruit and vegetable in the form of spray in the powdered rhombus.
상기 '현맥'은 쌀보리로서 도정하지 않은 배아와 내피층이 그대로 보존된 현미와 같은 보리를 의미하며, 겉보리나 현맥을 백미처럼 도정한 보리인 보리쌀과는 도정에 차이가 있는 다른 종류의 보리이다.The 'stem' refers to barley such as brown rice with embryo and endothelial layer preserved intact as naked barbarie, and barley which is different from the barley as barley, which is covered with barley or rhizome.
먼저, 상기 (a)단계에서는 도정하지 않은 현맥을 발아시킨다.First, in step (a), unspotted rhymes are germinated.
상기 '발아'는 현맥의 싹을 틔우는 것을 의미한다(즉 유근의 시원체인 백체가 나타나는 것을 말한다). 보리의 적절한 발아 온도 및 기간은 당 업계에서 공지되어 있다. 일반적으로 발아 온도가 높으면 발아 기간이 짧고, 발아 온도가 낮으면 발아 기간이 길다. 예컨대 현맥이 물을 충분히 흡수하도록(수분함량 35~40 중량%) 하여 발아시킬 때, 10 내지 25 ℃에서는 10 내지 30시간이 소요되며, 5 내지 10 ℃에서는 30 내지 60시간 정도이다. 본 발명에서는 현맥을 물에 침지시켜 수분을 충분히 흡수하도록 하고 10 내지 25 ℃의 온도에서 10 내지 30시간 보관(방치)하여 총 현맥수의 85 내지 90 중량%를 발아시켰다. 싹을 틔운(발아) 현맥의 수는 총 현맥수의 85 내지 90 중량%를 발아시키는 것이 다음 단계인 덱스트린(호정)화 단계에서 덱스트린화 효과가 높다는 점에서 총 현맥수의 85 내지 90 중량%를 발아시키는 것이 바람직하다. 또한, 유근(幼根)의 시원체(始原體)인 백체(白體)의 길이는 1 mm미만인 것이 바람직한데, 이는 백체의 길이가 1 mm미만인 것이 덱스트린(호정)화 단계에서 덱스트린화 효과가 높기 때문이다.The 'germination' means to shoot the stem of the stem (that is, the appearance of a baguette, which is the root of the root). Appropriate germination temperatures and durations of barley are well known in the art. Generally, if germination temperature is high, germination period is short, and if germination temperature is low, germination period is long. For example, it takes 10 to 30 hours at 10 to 25 DEG C and 30 to 60 hours at 5 to 10 DEG C in order to sufficiently absorb water (moisture content 35 to 40 wt%) and germinate. In the present invention, the rhizome is immersed in water to sufficiently absorb moisture, and is stored (left to stand) at a temperature of 10 to 25 DEG C for 10 to 30 hours to germinate 85 to 90 wt% of the total rhizome. The number of sprouting rhizomes is 85 to 90% by weight of the total rhizome count in that the germination of 85 to 90% by weight of the total rhizome counts the dextrinizing effect in the next stage of dextrinization Germination is preferable. In addition, it is preferable that the length of the white body as a primordial body of the radicle root is less than 1 mm, because the length of the body is less than 1 mm, which is a dextrinizing effect in the dextrinization step High.
다음으로, 상기 (b)단계에서는 상기 발아된 현맥을 덱스트린(호정)화 한다. 이때, 발아된 현맥을 덱스트린화 하기 전에 춘화처리하는 단계를 먼저 수행할 수 있다. Next, in step (b), the germinated limbs are dextrinized. At this time, the step of cultivating the germinated rhizome before dextrinization can be performed first.
상기 '춘화처리'는 발아시킨 현맥을 일정기간 동안 저온처리하는 것을 의미한다. 일반적으로 특정 작물은 그것의 특정 파종 시기가 있어서 다른 시기에 파종할 경우 외부 환경의 온도와 맞지 않아 개화가 되지 않거나 개화가 지연된다. 그것은 개화를 위해서는 그 작물에 맞는 온도가 일정 기간 유지되어야 하기 때문이다. 적절한 춘화처리는 온도 및 시간에 의하여 결정되는데, 현맥의 경우는 적절한 춘화처리 온도가 0 내지 15 ℃, 바람직하게는 0 내지 7 ℃, 보다 바람직하게는 0 내지 3 ℃이다. 상기 0 ℃ 이하에서는 춘화처리 효과가 감소하고, 7 ℃ 이상에서는 춘화처리 효과가 점차 감소하여 15 ℃를 넘어서면 아예 춘화처리가 되지 않는다. 한편, 춘화처리 기간은 하한에서는 20일 이상 바람직하게는 30일 이상 또는 40일 이상이며, 상한에 있어서는 120일 이하 바람직하게는 110일 이하, 100일 이하, 90일 이하, 80일 이하, 70일 이하, 60일 이하 또는 50일 이하이다. The " vernalization treatment " means treating the gummed stem at a low temperature for a certain period of time. In general, certain crops have their specific date of planting, so that if they are sown at different times, they do not match the temperature of the external environment and are not flowering or flowering is delayed. It is because the temperature for the crop must be maintained for a certain period in order to flow. The appropriate vernalization process is determined by the temperature and the time. In the case of the rhizome, the appropriate vernalization temperature is 0 to 15 캜, preferably 0 to 7 캜, more preferably 0 to 3 캜. When the temperature is below 0 ° C, the effect of the vulcanization treatment is reduced. When the temperature is above 7 ° C, the effect of the vulcanization treatment gradually decreases. On the other hand, the vernalization treatment period is 20 days or more, preferably 30 days or more, or 40 days or more at the lower limit, 120 days or less, preferably 110 days or less, 100 days or less, 90 days or less, 80 days or less, Or less, or 60 days or less, or 50 days or less.
본 발명에서는 발아된 현맥을 0 내지 3 ℃의 온도에서 40 내지 50일 동안 춘화처리한다. 상기 춘화처리 온도의 선택과 춘화처리기간의 선택은 당업자의 통상의 능력 범위에서 적절한 선택이 가능하다.In the present invention, germinated rhizomes are cultivated for 40 to 50 days at a temperature of 0 to 3 占 폚. The selection of the vernis processing temperature and the selection of the vernacular processing period can be appropriately selected within a range of ordinary skill in the art.
본 발명에서, 상기 덱스트린화는 60 내지 65 ℃의 온도 및 80 내지 100%의 습도하에서 밀폐된 상태로 7 내지 8시간 동안 정치(定置)시킴으로써 수행된다. 상기 온도는 아밀라제(amylase), 말타제(maltase), 프로타제(protease) 등 효소의 활성온도로서 춘화처리된 현맥이 가지는 아밀라제(amylase), 말타제(maltase), 프로타제(protease) 등의 효소에 의해서 덱스트린처리가 된다. 곡물이 포함하고 있는 탄수화물은 액상상태에서 효소, 산 또는 열에 의해 가수분해로 활성화되는 것이 원칙이다. 상기 춘화처리된 현맥의 수분함량으로는 덱스트린화가 느리게 진행되므로 이를 보완하기 위하여 7 내지 8시간의 덱스트린화 시간을 확보하는 것이 바람직하다. In the present invention, the dextrinization is carried out by setting at a temperature of 60 to 65 DEG C and a humidity of 80 to 100% in a sealed state for 7 to 8 hours. The temperature is the temperature of the enzyme such as amylase, maltase and protease, and is the temperature at which the enzymes such as amylase, maltase, protease, Is treated by dextrin. Carbohydrates contained in grains are hydrolyzed by enzymes, acids or heat in liquid phase. The dextrinization proceeds slowly as the water content of the rhizome treated rhizome, so it is desirable to secure a dextrinization time of 7 to 8 hours in order to compensate for this.
현맥의 외피층은 경질(硬質)의 섬유질(해미세루로이즈) 및 소수성의 왁스층으로 형성이 되어있어 과립형성 시 거친식감의 개선이 어렵다. 상기 현맥의 덱스트린화는 발효 미생물인 유산균이 현맥을 에너지원으로 이용하기에 적합한 형태, 즉, 글루코스나 말토오스 등이 다량 함유된 상태로 변화시키기 위한 것이다. 상기 현맥의 덱스트린화를 통해 유산균에 의한 현맥의 발효시간을 단축시키고, 발효 효율을 현저히 향상시킬 수 있으며, 유리당과 아미노산이 다량 증가된 현맥 과립을 제조하였다. The outer skin layer of the rhombus is formed of a hard fibrous material (hemicellulose) and a hydrophobic wax layer, and it is difficult to improve rough texture during granule formation. The dextrinization of the rhizome is intended to change the lactic acid bacteria, which are fermenting microorganisms, into a form suitable for use as a source of energy, that is, a state containing a large amount of glucose or maltose. By the dextrinization of the rhizome, the fermentation time of the rhizomes by the lactic acid bacteria was shortened, the fermentation efficiency was remarkably improved, and the rhizome granules with a large amount of free sugar and amino acid were prepared.
다음으로, 상기 (c) 단계에서는 덱스트린화된 현맥을 미강과 혼합한 후 유산균으로 발효시킨다. Next, in step (c), dextrinized rhizome is mixed with rice bran and fermented with lactic acid bacteria.
상기 유산균에 의한 발효를 용이하기 위하여 덱스트린화된 현맥과 미강을 분쇄하여 이용하는 것도 가능하다. In order to facilitate fermentation by the above-mentioned lactic acid bacteria, it is also possible to pulverize dextrinized rhizome and rice bran.
본 발명에 의하면, 상기 현맥 10 중량부에 대하여 미강 3 내지 15 중량부를 혼합할 수 있으나 이에 제한되는 것은 아니다. According to the present invention, 3 to 15 parts by weight of rice bran can be mixed with 10 parts by weight of the beeswax, but the present invention is not limited thereto.
상기 '미강'이란 현미에서 백미로 정미하는 과정에서 얻어지는 부산물로서, 쌀눈과 호분층을 포함하는 것을 말한다. 미강에는 레시친, 옥타코사놀, 오리자놀 및 토코페롤과 같은 생리활성 물질이 다량 분포되어 있으며, 다양한 생리활성을 지니는 것으로 알려져 있다. 예컨데, 중금속 해독, 항변비, 항콜레스테롤, 미백, 항고혈압 및 숙취해소 등에 활성을 나타낸다. 이러한 미강은 거친 식감을 나타내며, 체내이용도가 낮다. As used herein, the term "rice bran" refers to a by-product obtained from the process of rice rice to white rice, including rice husks and rice hulls. Rice bran has a large amount of physiologically active substances such as lecithin, octacosanol, orzanol and tocopherol, and it is known to have various physiological activities. For example, it exhibits activities such as heavy metal detoxification, anti-constipation, anti-cholesterol, whitening, anti-hypertension and hangover resolution. Such rice bran shows a rough texture and has low utilization rate in the body.
유산균은 비병원성균으로 인간의 장내에 서식하는 유익한 미생물 중의 한 종류로서 혐기적인 조건 및 낮은 pH에서도 생육이 가능하다. 상기 유산균은 정장 작용을 수행하고 당류 및 식이섬유를 주 영양분으로 흡수하여 발효를 수행하며, 이러한 발효를 통해 다량의 젖산을 생성한다. 유산균에 의해 발효가 되게 되면 독특한 맛과 향을 내게 되어 관능적 특성이 향상되고, 유기물이 분해되면서 여러 종류의 생리활성 물질들을 생성하여 성인병 예방, 항암효과, 항균효과 등 다양한 효능이 나타나게 된다. 본 발명에 의하면, 상기 유산균 발효는 35 내지 50 ℃의 온도, 바람직하게는 42 내지 46 ℃의 온도에서 수행될 수 있으며, 36 내지 60시간 동안, 바람직하게는 40 내지 52시간 동안 수행될 수 있고, 밀폐된 상태인 것이 보다 바람직하다. 상기 온도, 시간 및 환경 조건에서 수행하는 것이 발효효율이 극대화되며, 풍미가 우수한 현맥 과립이 제조되었다. Lactic acid bacteria is a non-pathogenic bacterium that is one of the beneficial microorganisms inhabiting human intestines and can grow under anaerobic conditions and low pH. The lactic acid bacteria perform a sucking action, perform fermentation by absorbing sugars and dietary fiber as main nutrients, and produce a large amount of lactic acid through such fermentation. When fermented by lactic acid bacteria, it gives distinctive taste and aroma, and its sensory characteristics are improved. As the organic matter is decomposed, various kinds of physiologically active substances are produced and various effects such as prevention of adult disease, anticancer effect and antibacterial effect are exhibited. According to the present invention, the lactic acid fermentation can be carried out at a temperature of 35 to 50 DEG C, preferably 42 to 46 DEG C, for 36 to 60 hours, preferably 40 to 52 hours, It is more preferable that it is in a sealed state. The fermentation efficiency was maximized at the above temperature, time, and environmental conditions, and rhizome granules having excellent flavor were produced.
상기 유산균은 통상의 유산균을 이용할 수 있으며, 예를 들어 복합 유산균(L. bularicus와 L. plantarum)일 수 있고, 현맥 100 중량부에 대하여 유산균 1 내지 5 중량부로 처리될 수 있다. The lactic acid bacteria may be conventional lactic acid bacteria. For example, they may be lactic acid bacteria ( L. bularicus and L. plantarum ), and may be treated with 1 to 5 parts by weight of lactic acid bacteria per 100 parts by weight of rhizome.
본 발명에 의하면, 상기 유산균으로 발효된 현맥에 과채 효소분해물을 분사한 다음 1 내지 6시간 동안 숙성시키는 단계를 더 포함할 수 있다. 상기 과채 효소분해물은 과일 또는 채소를 베타-글루카나아제(β-glucanase), 헤미셀룰라아제(hemicellulase), 셀룰라아제(cellulase), 자일란나아제(xylanase), 펙티나아제(pectinase) 및 아라비나아제(arabinase) 중에서 선택되는 1종 또는 2종 이상의 세포벽 분해효소로 효소분해한 다음 효소를 실활시키고, 착즙하여 제조된 것일 수 있다. 상기 세포벽 분해효소로 상용효소를 이용할 수 있는데 상기 상용효소는 에코니타제(Econitase), 라피다아제(Rapidase), 비스코자임(Viscozyme), 셀루클라스트 (Celluclast), 펙티넥스(Pectinex), 로하멘트(Rohament), 울트라플로(Ultraflo), 사이토라아제(Cytolase) 및 울트라자임(Ultrazyme)으로 이루어진 군 중에서 선택되는 1종을 단독 또는 2종 이상의 상용효소를 혼합하여 이용할 수도 있다. 상기 효소는 10 내지 500 unit/과채 100g으로 처리될 수 있다. According to the present invention, it is possible to further include a step of spraying an enzyme hydrolyzate of the fermented fermented lactic acid bacteria, followed by aging for 1 to 6 hours. The enzyme hydrolyzate of the fruit is a fruit or a vegetable which is mixed with beta-glucanase, hemicellulase, cellulase, xylanase, pectinase and arabinase ), Inactivating the enzyme with one or two or more kinds of cell wall degrading enzymes selected from the group consisting of yeast extract, As the cell wall degrading enzyme, a common enzyme may be used. Examples of the enzyme include econitase, Rapidase, Viscozyme, Celluclast, Pectinex, (Rohament), Ultraflo, Cytolase, and Ultrazyme may be used alone or in combination of two or more kinds of enzymes. The enzyme may be treated with 10 to 500 units / 100 g of enzyme.
상기 유산균으로 발효된 현맥을 과채 효소분해물로 숙성시키는 단계를 더 포함하면 그렇지 않은 경우에 비하여 현맥 과립의 기능성 성분의 함량이 증대될 뿐만 아니라, 식감이 부드럽고 풍미가 향상되어 관능평가에서 매우 우수한 평가를 받았다. The step of aging the rhizome fermented with the lactic acid bacterium with an enzymatic hydrolyzate of hydrolyzate is not only an increase in the content of the functional ingredient of the chrysanthemum granules but also an excellent evaluation in the sensory evaluation because the texture is improved and the flavor is improved received.
다음으로, 상기 발효된 현맥을 분말화한 다음 유동층 건조기를 이용하여 상기 분말화된 현맥에 과채 농축액을 스프레이 형태로 분사하면서 유동층 건조(fluid bed crying) 방식으로 미립 형태의 과립을 생성시킨다. Next, the fermented rhizome is pulverized and then granulated in a fluid bed crying method to form granules in a granular form while spraying the fruit juice concentrate into the powdered rhombus using a fluid bed drier.
상기 과채 농축액은 과일 또는 채소를 착즙하여 농축한 농축액; 또는 과일 또는 채소를 세포벽 분해효소로 효소처리한 후 착즙하여 농축한 농축액일 수 있으며, 상기 과채는 감귤, 브로콜리, 양배추 및 당근 중에서 선택되는 것일 수 있다. 여기에서, 상기 과일 또는 채소를 세포벽 분해효소로 효소처리한 후 착즙하여 농축한 농축액은 상기 과채 효소분해물과 동일한 방법으로 제조된 것일 수 있다. Wherein the fruit and vegetable concentrate is a concentrated fruit and vegetable concentrate; Or a concentrate obtained by enzymatically treating fruits or vegetables with cell wall degrading enzymes and then concentrating them by juice, and the fruit can be selected from citrus fruits, broccoli, cabbage and carrots. Herein, the concentrate obtained by enzymatically treating the fruit or vegetable with the cell wall degrading enzyme and then concentrating the concentrate may be one prepared by the same method as the above-described enzyme-degrading enzyme.
유동층건조기는 과립이나 미립의 형태로 형성되는 분말을 건조시켜 상품화하기 위하여 유공판의 아래쪽에서 열풍을 적당한 유속으로 보내어 유공판 상의 분립체에 유동층을 형성시키면서 건조하는 방식으로, 특히 수분을 포함한 분말은 유통과정에서 수분에 의해 부패되기 때문에 화학회사나 제약회사 등에서 약품을 건조시키기 위해 많이 사용하는 방법이다. The fluidized bed dryer is a method in which hot air is blown at a proper flow rate from the lower side of a perforated plate to dry the powder formed in the form of granules or fine granules and dried to form a fluidized bed on the granules on the perforated plate. Because it is corroded by moisture in the distribution process, it is a method widely used by chemical companies and pharmaceutical companies to dry chemicals.
본 발명에서는 유동층 건조방식을 이용함으로써 현맥에 과채 농축액이 높은 분산도로 분산되어 식감이 부드럽고, 목넘김이 우수하며, 풍미가 향상된 미립 형태의 과립을 제조하였다.
According to the present invention, the granule of the present invention is dispersed in a highly dispersed state to produce a granule having smooth texture, excellent necking, and improved flavor by using a fluid bed drying method.
이하, 본 발명의 이해를 돕기 위하여 바람직한 실시예를 제시하나, 하기 실시예는 본 발명을 예시하는 것일 뿐 본 발명의 범주 및 기술사상 범위 내에서 다양한 변경 및 수정이 가능함은 당업자에게 있어서 명백한 것이며, 이러한 변형 및 수정이 첨부된 특허청구 범위에 속하는 것도 당연한 것이다.
It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the spirit or scope of the present invention. Such variations and modifications are intended to be within the scope of the appended claims.
실시예 1.Example 1.
도정하지 않은 현맥 10 kg을 물 20 ℓ에 침지시키고 15 ℃에서 8시간 동안 방치하여 현맥이 충분히 수분을 흡수하도록 한 후 수분을 흡수한 현맥을 채반에 담아 수분을 제거하고 천을 덮어 18 ℃에서 12시간 동안 방치하여 전체 현맥수의 85 중량%이상을 발아시킨 다음 1 ℃에서 40일 동안 보관하여 춘화처리하였다. 그 후 춘화처리된 현맥을 65 ℃ 온도 및 90% 포화습도하에서 8시간 동안 덱스트린화시켰다. 덱스트린화 된 현맥에 미강을 혼합 한 후 분쇄기를 이용하여 분말화시키고, 진공발효건조기를 이용하여 진공상태의 45 ℃에서 48시간 동안 유산균으로 발효하였다. 발효물을 건조한 후, 분쇄기를 이용하여 분말화시키고 유동층 건조기를 이용하여 감귤 농축액을 스프레이 분사하면서 과립을 제조하였다.
10 kg of undiluted persimmon was immersed in 20 ℓ of water and allowed to stand at 15 ° C for 8 hours to allow the persimmon to absorb enough moisture. Then, the persimmon absorbing moisture was removed from the vat by removing the water, Over 85% by weight of the total number of the rhizome was germinated and stored at 1 캜 for 40 days. The vernalized rhizome was then dextrinized at 65 ° C and 90% saturated humidity for 8 hours. Raw corn was mixed with dextrinized rhizomes, pulverized using a pulverizer, and fermented with lactic acid bacteria in a vacuum fermentation dryer at 45 ° C for 48 hours. The fermented material was dried, pulverized using a pulverizer, and granulated while spraying a citrus concentrated liquid using a fluid bed drier.
실시예 2Example 2
실시예 1과 동일한 방법으로 과립을 생성하되, 감귤 농축액 대신에 브로콜리농축액을 스프레이 분사하면서 과립을 제조하였다.
The granules were produced in the same manner as in Example 1 except that the broccoli concentrate was spray-sprayed instead of citrus concentrate to prepare granules.
실시예 3Example 3
실시예 1과 동일한 방법으로 과립을 생성하되, 감귤 농축액 대신에 양배추 농축액을 스프레이 분사하면서 과립을 제조하였다.
The granules were produced in the same manner as in Example 1 except that the cabbage concentrate was sprayed instead of citrus concentrate to prepare granules.
실시예 4Example 4
실시예 1과 동일한 방법으로 과립을 생성하되, 감귤 농축액 대신에 당근 농축액을 스프레이 분사하면서 과립을 제조하였다.
Granules were produced in the same manner as in Example 1 except that granules were prepared by spraying a carrot concentrate instead of citrus concentrate.
실시예 5Example 5
유산균으로 발효된 현맥을 분말화하기 전에 유산균으로 발효된 현맥 100 중량부에 감귤 효소분해물 5 중량부를 첨가하여 3시간 동안 숙성시키는 단계를 더 포함하여 실시예 1과 동일한 방법으로 과립을 제조하였다.
The granules were prepared in the same manner as in Example 1, except that 5 parts by weight of citrus enzymatic degradation product was added to 100 parts by weight of fermented lactic acid bacteria before pulverization of lactic acid fermented with lactic acid bacteria and aged for 3 hours.
비교예 1Comparative Example 1
상기 실시예 1과 동일하게 실시하되 덱스트린화 처리를 생략하여 과립을 제조하였다.
The procedure of Example 1 was repeated except that the dextrinization treatment was omitted.
비교예 2.Comparative Example 2
상기 실시예 1과 동일하게 실시하되 유산균 발효를 생략하여 과립을 제조하였다.
The granulation was carried out in the same manner as in Example 1 except that lactic acid bacteria fermentation was omitted.
비교예 3.Comparative Example 3
상기 실시예 1과 동일하게 실시하되 감귤 농축액 대신에 물을 분사하면서 과립을 제조하였다.
The granules were prepared in the same manner as in Example 1 except that water was sprayed instead of citrus concentrated liquid.
실시예Example
시험예 1. 추출수율 평가Test Example 1. Evaluation of extraction yield
실시예 1 내지 4의 과립 10 g을 열수 및 에탄올 수용액으로 추출하여 1 내지 8의 추출물을 얻었으며, 건조중량 및 추출수율을 평가하여 하기 표 1에 나타내었다.10 g of the granules of Examples 1 to 4 were extracted with hot water and aqueous ethanol solution to obtain extracts 1 to 8. The dry weight and the extraction yield were evaluated and are shown in Table 1 below.
열수
Heat number
70% 에탄올
70% ethanol
대부분의 첨가군이 30% 이상의 높은 추출수율을 나타내었으며, 감귤의 경우만 다소 낮은 추출수율을 보였다. 열수추출물의 추출수율은 25.0 내지 35.4%이고, 에탄올 추출수율은 22.9 내지 32.1%로 나타나 열수추출 방법이 추출수율에서는 보다 유리한 것으로 평가되었다.
Most of the extracts showed high extraction yields of over 30%, and citrus fruits showed a somewhat lower extraction yield. The extraction yield of the hot water extract was 25.0 to 35.4% and the ethanol extraction yield was 22.9 to 32.1%, which indicates that the hot water extraction method is more advantageous in the extraction yield.
시험예 2. 항산화 활성 검증Test Example 2. Antioxidant Activity Test
1) 총 폴리페놀 함량분석1) Total polyphenol content analysis
Folin-Denis의 방법(AOAC 1980)으로 총 폴리페놀의 함량을 분석하였다. 구체적으로, 1 내지 8의 추출물 200μL와 증류수 1,800μL을 혼합하고, Folin-Ciocalteau's phenol reagent 200μL을 가하여 잘 섞은 후 5분간 상온에서 반응시켰다. 여기에 2M Na2CO3 400μL을 가하여 혼합하고, 증류수를 가하여 4 mL로 조정한 후, 상온에서 1시간 동안 반응시켰다. 반응 종료 후, 725 nm에서 흡광도를 측정하고, gallic acid(Sigma Chemical Co)를 이용한 검량선과 비교하여 총 폴리페놀 함량을 mg gallic acid equivalents(GAE)/g로 나타내었다.The total polyphenol content was analyzed by Folin-Denis method (AOAC 1980). Specifically, 200 μL of the extracts 1 to 8 and 1,800 μL of distilled water were mixed and 200 μL of Folin-Ciocalteau's phenol reagent was added thereto, followed by reaction at room temperature for 5 minutes. 400 μL of 2M Na 2 CO 3 was added thereto, mixed, and the mixture was adjusted to 4 mL with distilled water, followed by reaction at room temperature for 1 hour. After completion of the reaction, the absorbance was measured at 725 nm, and the total polyphenol content was expressed as mg gallic acid equivalents (GAE) / g in comparison with a calibration curve using gallic acid (Sigma Chemical Co).
열수
Heat number
70% 에탄올
70% ethanol
페놀 화합물은 식물계에 광범위하게 분포되어 있으며 대부분 세포벽 다당류 및 리그닌 등과 에스테르 결합을 이루고 있거나, 중합체로 존재하며 수산기를 통한 수소공여와 페놀 고리구조의 공명 안정화에 의하여 항산화능을 나타내어 체내의 항산화 체계와 함께 자유기로부터 조직을 보호해 주는 역할을 하는 것으로 알려져 있다. 열수추출물의 총 폴리페놀 함량은 6.8~16.7 mg GAE/g이었으며 에탄올 추출물의 총 폴리페놀 함량은 16.0~19.2 mg GAE/g이었다. 총 폴리페놀 함량은 전체적으로 에탄올 추출물에서 높게 나타났다.
The phenolic compounds are widely distributed in the vegetable field and most of them have ester bonds with cell wall polysaccharides and lignin, or they are present as polymers, and they show antioxidant ability by hydrogen donation through hydroxyl group and resonance stabilization of phenolic ring structure, It is known to play a role in protecting tissues from free radicals. Total polyphenol content of hot water extract was 6.8 ~ 16.7 mg GAE / g and total polyphenol content of ethanol extract was 16.0 ~ 19.2 mg GAE / g. Total polyphenol content was higher in ethanol extract as a whole.
2) 총 플라보노이드 함량분석2) Total flavonoid content analysis
1 내지 8의 추출물을 20 mg/mL의 농도가 되게 증류수에 희석한 후 200μL을 취하고 여기에 에탄올 800μL와 5% NaNO2 60μL을 첨가하여 균질하게 혼합한 후 5분간 실온에서 반응시켰다. 여기에 10% AlCl3을 60μL 첨가하고 실온에서 다시 5분간 반응시켰다. 다음으로 1M NaOH 용액을 400μL 첨가하여 1분간 상온에서 반응시키고 증류수 500μL을 가하여 균질화시킨 후, 200μL을 취하여 96 well plate에 분주한 뒤 415 nm에서 흡광도를 측정하였다. 표준물질로는 quercetin을 이용하여 표준곡선을 작성하였고, 추출물의 총 플라보노이드 함량은 mg quercetin equivalents(QE)/g로 나타내었다.The extracts 1 to 8 were diluted with distilled water to a concentration of 20 mg / mL, and then 200 μL of the extract was added. To this, 800 μL of ethanol and 60 μL of 5% NaNO 2 were added and homogeneously mixed and reacted at room temperature for 5 minutes. To this, 60 μL of 10% AlCl 3 was added, and the mixture was further reacted at room temperature for 5 minutes. Next, 400 μL of 1 M NaOH solution was added, reacted at room temperature for 1 minute, homogenized by adding 500 μL of distilled water, and 200 μL of the sample was dispensed into a 96-well plate and absorbance was measured at 415 nm. Standard curves were prepared using quercetin as a standard, and the total flavonoid content of the extract was expressed as mg quercetin equivalents (QE) / g.
열수
Heat number
70% 에탄올
70% ethanol
플라보노이드는 과일, 야채, 견과류를 비롯한 식물의 줄기, 뿌리, 껍질에 분포하는 색소성분의 하나로서 diphenylprogane(C6-C3-C6)을 기본골격으로 한 phenol계 화합물의 총칭으로 다양한 생리적 기능을 가지고 있다. 이러한 플라보노이드는 유리상태로 존재하나 대개의 경우 당류와 결합한 배당체의 형태로 존재하고 있으며, 이 배당체를 형성하고 있는 당류는 산, 알칼리, 효소 등에 의해서 쉽게 가수분해 되며, 배당체의 경우보다 유리 상태가 생리활성능력이 더 강한 것으로 알려져 있다. 열수추출물의 총 플라보노이드 함량은 1.4~6.1 mg QE/g이었으며 에탄올 추출물의 총 폴리페놀 함량은 9.7~11.6 mg QE/g이었다. 총 플라보노이드 함량은 전체적으로 에탄올 추출물에서 높게 나타났으며, 특히 감귤이 첨가된 실시예 1에서 높게 나타났다.
Flavonoids are a generic term for phenolic compounds with diphenylprogane (C6-C3-C6) as one of the pigment components distributed in the stem, root, and skin of plants, including fruits, vegetables and nuts. These flavonoids exist in the free state, but in most cases they exist in the form of glycosides combined with saccharides. Saccharides forming these glycosides are easily hydrolyzed by acids, alkalies, enzymes, etc., Active activity is known to be stronger. The total flavonoid content of hot water extract was 1.4 ~ 6.1 mg QE / g and the total polyphenol content of ethanol extract was 9.7 ~ 11.6 mg QE / g. The total flavonoid content was higher in the ethanol extract as a whole and higher in the citrus added Example 1.
3) DPPH 자유유리기 소거활성3) DPPH free radical scavenging activity
DPPH 자유유리기 소거 활성은 시료의 여러 농도에 0.4 mM DPPH 용액을 동량 첨가하여 실온에서 30분간 방치한 후 517 nm에서 흡광도를 측정하였다. 대조군(MeOH)의 흡광도와 비교하여 흡광도를 감소시키는 정도를 %로 나타내었으며, 양성대조군으로는 ascorbic acid를 사용하였으며, 25 ㎍/mL에서 96.8으로 나타났다. The DPPH free radical scavenging activity was measured by adding 0.4 mM DPPH solution to various concentrations of the sample, incubating at room temperature for 30 minutes, and measuring the absorbance at 517 nm. Absorbance was reduced by% compared with the absorbance of the control (MeOH), ascorbic acid was used as a positive control, and 96.8 at 25 ㎍ / mL.
division
Experimental group
Addition group
Extraction method
열수
Heat number
70% 에탄올
70% ethanol
유리 라디칼은 생물학적 손상의 주요 요인으로 알려져 있으며, 전자공여작용은 라디칼에 전자를 공여하여 식품중의 지방질 산화를 억제하는 목적으로 사용되고 있을 뿐만 아니라 인체내에서 활성 라디칼에 의한 노화를 억제하는 작용의 목적으로 이용되고 있어, DPPH는 천연 항산화제의 유리 라디칼 소거능을 평가하는데 일반적으로 사용되고 있다. 열수추출물의 DPPH 라디칼 소거활성은 1,000 ㎍/mL 농도에서 16.2~37.0%의 소거활성을 나타내었으며, 2,500㎍/mL 농도에서는 모든 실시예에서 61.8% 이상의 높은 DPPH 라디칼 소거활성을 보였다. 에탄올 추출물인 경우 열수 추출물보다 더 높은 DPPH 라디칼 소거활성을 나타내었는데 1,000 ㎍/mL 농도에서는 30.7~32.6%, 2,500 ㎍/mL 농도에서 85.5~100.5%의 소거활성을 보였다.
Free radicals are known to be a major cause of biological damage. The electron donating action is used not only for the purpose of inhibiting lipid oxidation in foods by donating electrons to radicals, but also for the purpose of inhibiting aging by active radicals in the body , And DPPH is generally used to evaluate the free radical scavenging ability of natural antioxidants. The DPPH radical scavenging activity of the hydrothermal extract showed 16.2 ~ 37.0% scavenging activity at 1,000 ㎍ / mL concentration and 61.8% or more DPPH radical scavenging activity at all at 2,500 ㎍ / mL concentration. The ethanol extract showed higher DPPH radical scavenging activity than that of the hot - water extract. The DPPH radical scavenging activity was 30.7 ~ 32.6% at 1,000 ㎍ / mL and 85.5 ~ 100.5% at 2,500 ㎍ / mL concentration.
4) Xanthine oxidase 억제활성4) Xanthine oxidase inhibitory activity
1 내지 8의 추출물 50μL에 1 mM xanthine, 2 mM EDTA를 50μL 가하고 50 mU/mL xanthine oxidase 효소를 100μL 가하고 1시간 반응 후 290 nm에서 흡광도를 측정하였으며, 양성대조군으로는 allopurinol을 사용하였으며, 5 ㎍/mL에서 89.4로 나타났다(억제활성; Xanthine oxidase inhibitory activity at 5,000㎍/mL).50 μL of 1 mM xanthine and 2 mM EDTA was added to 50 μL of extracts 1 to 8, 100 μL of 50 mU / mL xanthine oxidase enzyme was added, and the absorbance was measured at 290 nm after 1 hour of reaction. Allopurinol was used as a positive control, / mL and 89.4 (inhibitory activity; Xanthine oxidase inhibitory activity at 5,000 g / mL).
열수
Heat number
70% 에탄올
70% ethanol
Xanthine oxidase는 purine 대사에 관여하는 효소로서 xanthine 또는 hypoxanthine의 산소를 떼어내면서 과산화수소(H2O2)를 생성하게 되고 나머지 골격이 uric acid를 형성하여 혈장내에 과량 존재하게 되면 골절에 축적되어 심한 통증을 유발하는 통풍과 신장에 침착되어 신장 질환을 일으키는 효소이다. 통풍 치료는 혈중 요산의 생성 억제제인 allopurinol과 신장의 요산 재흡수 억제제인 probenecid 및 benzbromarone 등이 이용되고 있으나, 골수 억제, 과민 반응 및 간 독성 등과 같은 부작용이 있는 것으로 알려지고 있다. 통풍 치료제인 allopurionol를 대체하기 위하여 xanthine oxidase 억제활성을 지니고 있는 물질을 천연 소재에서 찾고자 하는 연구들이 진행되고 있다. Xanthine oxidase 억제 활성은 추출물의 농도가 5,000 ㎍/mL일 때, 열수 추출물은 22.7~35.4%를 나타냈으며, 에탄올 추출물은 68.1~112.1%의 xanthine oxidase 억제 활성을 나타내어 당근 > 양배추 > 브로콜리 > 감귤이 첨가된 순으로 높은 억제활성을 나타내었다.
Xanthine oxidase is an enzyme involved in purine metabolism. It removes oxygen from xanthine or hypoxanthine and generates hydrogen peroxide (H 2 O 2 ). When the remaining skeleton forms uric acid and is present in plasma excessively, it accumulates in the fracture and causes severe pain It is an enzyme that causes kidney disease by being deposited in induced gout and kidney. Allopurinol, an inhibitor of the production of uric acid in the blood, and probenecid and benzbromarone, inhibitors of uric acid reabsorption in the kidney, have been used to treat gout. However, it is known that there are side effects such as bone marrow suppression, hypersensitivity reaction and liver toxicity. Studies are underway to find substances with xanthine oxidase inhibitory activity in natural materials to replace allopurinol, a gout remedy. The inhibitory activity of xanthine oxidase was 22.7 ~ 35.4% in the extract of 5,000 ㎍ / mL, and 68.1 ~ 112.1% of the ethanol extract showed the activity of xanthine oxidase. The extracts of carrot, cabbage, broccoli, citrus , Respectively.
시험예Test Example 2. 항고혈압 활성 검증 2. Verification of antihypertensive activity
항고혈압 활성을 검증하기 위하여 Angiotensin converting enzyme(ACE) 저해활성을 평가하였다. ACE 저해활성은 Kuba 등의 방법(2003)에 따라 측정하였다. 구체적으로, 추출시료 0.05 mL에 assay mixture(100 mM potassium phophate buffer pH 8.3, 300 mM NaCl, 5 mM hip-pury-his-leu)을 0.2 mL을 가한 후 37 ℃에서 5분간 반응 후 ACE 효소액 0.2 mL을 가하고 37 ℃에서 1시간 반응 후 1N HCl 0.5 mL을 가하여 반응을 정지시킨다. 이때 대조구 실험은 반응을 정지 시킨 효소액을 시료에 첨가하였고, blank는 증류수를 사용하였다. Ethyl acetate 3 mL을 가하여 30초간 잘 섞어준 후 3000 rpm에서 10 분간 원심분리하여 ethyl acetate층을 새 tube에 옮긴 후 80℃에서 완전히 건조시킨 후 1 mL 증류수에 녹이고 228 nm에서 흡광도를 측정하였으며, blank를 대조군으로 하여 저해율을 계산하였으며 양성대조군으로 captopril를 사용하였으며, 1 ㎍/mL에서 68.2로 나타났다.Angiotensin converting enzyme (ACE) inhibitory activity was evaluated to verify antihypertensive activity. ACE inhibitory activity was measured according to the method of Kuba et al. (2003). Specifically, 0.2 mL of the assay mixture (100 mM potassium phophate buffer, pH 8.3, 300 mM NaCl, 5 mM hip-pury-his-leu) was added to 0.05 mL of the extracted sample and incubated at 37 ° C for 5 minutes. And the reaction was allowed to proceed at 37 ° C for 1 hour. Then, 0.5 mL of 1N HCl was added to terminate the reaction. At this time, in the control experiment, the enzyme solution in which the reaction was stopped was added to the sample, and blank was used in distilled water. The ethyl acetate layer was transferred to a new tube, dried thoroughly at 80 ° C, and then dissolved in 1 mL of distilled water. The absorbance at 228 nm was measured. The blank The inhibition rate was calculated by using captopril as a positive control and 68.2 at 1 ㎍ / mL.
열수
Heat number
70% 에탄올
70% ethanol
Angiotensin Ⅰ은 ACE에 의해 angiotensin Ⅱ로 전환되며, 이 angiotensin Ⅱ는 혈압 상승의 원인이 되므로 ACE 저해는 angiotensin Ⅱ로 전환되는 것을 차단시켜 혈압 상승을 막아주는 것으로 알려지고 있음에 따라 ACE 저해 활성은 항고혈압 활성 실험에 널리 이용되고 있다. 열수 추출물인 경우 23.9~38.8%의 ACE 저해 활성을 나타내었으며, 에탄올 추출물의 경우 36.5~51.5%로 열수 추출물과 비교했을 때 다소 높은 ACE 억제 활성을 나타내었다. 특히, 감귤이 첨가된 에탄올 추출물인 실시예 5에서 가장 높은 ACE 억제 활성을 나타내었다.
Since angiotensin Ⅰ is converted to angiotensin Ⅱ by ACE and angiotensin Ⅱ is a cause of blood pressure increase, it is known that ACE inhibition prevents angiotensin Ⅱ from being converted into angiotensin Ⅱ, And is widely used in active experiments. The ACE inhibitory activity was 23.9 ~ 38.8% in the hot water extract and 36.5 ~ 51.5% in the ethanol extract. In particular, the highest ACE inhibitory activity was shown in Example 5, which is an ethanol extract added with citrus.
시험예 3. 항염증 활성 검증Test Example 3. Anti-inflammatory activity assay
항염증 활성을 검증하기 위하여 NO 생성 저해능을 평가하였다. 실험에 사용된 마우스 대식세포인 RAW 264.7 cells은 한국세포주은행(KCLB, Korea Cell Line Bank, Seoul, Korea)에서 분양받아 사용하였다. RAW 264.7 cells은 10% 소태아혈청(fetal bovine serum, FBS, Gibco, Grand Island, NY, USA)과 항생제(250 units/mL, penicillin, 250 mg/mL streptomycin, Sigma-Aldrich Co., St. Louis, MO, USA)를 포함하는 DMEM(Gibco) 배지를 사용하여 37 ℃, 5% CO2 조건에서 배양하였으며, 2일 후 RAW 264.7 cells이 80% confluent 한 상태에서 세포를 분리하여 3,000 rpm에서 3분간 원심분리 한 후 현탁하여 사용하였다.In order to test anti-inflammatory activity, NO production inhibition was evaluated. The mouse macrophages RAW 264.7 cells used in the experiments were purchased from KCLB (Korea Cell Line Bank, Seoul, Korea). RAW 264.7 cells were treated with antibiotics (250 units / mL, penicillin, 250 mg / mL streptomycin, Sigma-Aldrich Co., St. Louis, MO) with 10% fetal bovine serum (FBS, Gibco, The cells were cultured at 37 ° C and 5% CO 2 using DMEM (Gibco) medium containing 2 % (w / v), MO, USA) Centrifuged and suspended.
곡물 유산균 발효제품이 세포의 생존에 미치는 영향은 3-(4,5-dimethylthiazol-2 yl)-2,5-diphenyltetrazolium bromide(MTT, Amresco, Solon, OH, USA) 방법을 이용하여 측정하였다. 구체적으로, 96 well plates에서 5 X 105 cells/well 농도로 RAW 264.7 cells을 분주한 뒤 24시간 동안 배양한 다음 농도별 시료를 세포에 처리한 후 1시간 뒤에 lipopolysaccharides(LPS)를 1 ㎍/mL씩 처리하여 24시간 동안 배양하였다. 이 후 배지를 제거한 후 5 mg/mL 농도의 MTT 용액을 10μL씩 넣어 37 ℃에서 2시간 반응시킨 다음 dimethyl sulfoxide(DMSO, Amresco)를 100μL씩 가해 10분간 교반하여 ELISA reader(Epoch, Bioteck, Winooski, VT, USA)로 570 nm에서 흡광도를 측정하였다. 세포 생존율은 시료 대신 3차 증류수를 처리한 대조군에 대한 백분율을 산출하였다.The effect of lactic acid fermentation products on cell survival was measured by 3- (4,5-dimethylthiazol-2 yl) -2,5-diphenyltetrazolium bromide (MTT, Amresco, Solon, OH, USA). The cells were cultured for 24 hours at a concentration of 5 × 10 5 cells / well in 96-well plates. After 1 hour, the cells were treated with lipopolysaccharides (LPS) at 1 μg / mL And cultured for 24 hours. After the medium was removed, 10 μL of 5 mg / mL MTT solution was added and reacted at 37 ° C. for 2 hours. 100 μL of dimethyl sulfoxide (DMSO, Amresco) was added to each well and the mixture was stirred for 10 minutes. An ELISA reader (Epoch, Bioteck, Winooski, VT, USA) at 570 nm. The cell survival rate was calculated as a percentage of the control group treated with the third distilled water instead of the sample.
RAW 264.7 cells을 5 X 105 cells/well 농도로 24 well plate에 분주하여 24시간 배양한 후 열수 추출물 및 에탄올 추출물을 각각 125, 250, 500, 1,000, 2,000 ㎍/mL의 농도로 처리한 다음, 1시간 후에 LPS를 1 ㎍/mL씩 처리하여 24시간 동안 배양한 후 배양액을 회수하여 원심분리(3,000 rpm, 5 min, 4℃)하여 세포 배양 상층액을 얻었으며 이를 nitric oxide(NO) 생성량 측정에 사용하였다.RAW 264.7 cells were plated on a 24-well plate at a concentration of 5 × 10 5 cells / well and cultured for 24 hours. The hot-water extracts and ethanol extracts were treated at 125, 250, 500, 1,000 and 2,000 μg / After 1 hour, the cells were treated with 1 ㎍ / mL of LPS for 24 hours. The culture was recovered and centrifuged (3,000 rpm, 5 min, 4 ℃) to obtain a cell culture supernatant. Lt; / RTI >
세포로부터 생성된 NO의 양은 세포 배양액 중에 존재하는 NO2 -의 형태로 Griess reagent system(Promega, Madison, WI, USA)을 이용하여 측정하였다. 세포 배양액 50μL와 sulfanilamide solution 50μL를 혼합하여 상온에서 10분간 반응시켰다. 여기에 NED 용액을 50μL 혼합하여 상온에서 다시 10분간 반응시킨 후 ELISA reader를 이용하여 540 nm에서 흡광도를 측정하였고, sodium nitrate로 표준곡선을 작성하여 NO 함량을 산출하였다.
The amount of NO produced from the cells was measured using the Griess reagent system (Promega, Madison, WI, USA) in the form of NO 2 - present in the cell culture. 50 μL of cell culture solution and 50 μL of sulfanilamide solution were mixed and reacted at room temperature for 10 minutes. 50 μL of NED solution was added and reacted for 10 min at room temperature. Absorbance was measured at 540 nm using an ELISA reader. A standard curve was prepared with sodium nitrate to calculate NO content.
Nitric oxide(NO)는 생리적 또는 병리적 상황에서 중요한 역할을 하는 조절 인자로, 적절한 농도의 NO는 생리적으로 평활근의 이완, 혈소판 응집 억제, 면역 조절, 혈관 확장, 신경전달 등의 기능을 수행한다. 면역세포에서 nitric oxide synthase(NOS)에 의해 생성되는 NO는 외부 자극에 의해 발현되어 외부로부터 침입한 미생물이나 종양세포를 파괴하는 자기방어 물질로도 작용하여 생리학적으로 중요한 역할을 한다. 그러나 과도한 NO의 생성은 세포의 염증을 유발하는 인자로 작용하여 여러 가지 만성 염증성 질환을 유발하는 원인이 된다. 체내의 자유라디칼에 의해서 조직 손상이 유발되거나 감염이 발생하면 염증 반응이 유도되는데, 대표적으로 대식세포 등이 반응하여 사이토카인을 생성하고, inducible nitric oxide synthase(iNOS)의 발현이 증가하여 많은 양의 NO가 생성되므로 iNOS의 발현 억제를 통해 항염증 활성을 평가할 수 있다. LPS는 산화적 스트레스를 유발하여 gram 음성 세균의 세포벽 물질로서 면역 세포 등을 자극하여 NO 생성을 증가시킨다고 보고되어 있다.Nitric oxide (NO) is a regulatory factor that plays an important role in physiological or pathological situations. The appropriate concentration of NO functions physiologically as smooth muscle relaxation, platelet aggregation inhibition, immune regulation, vasodilation, and neurotransmission. NO produced by nitric oxide synthase (NOS) in the immune cells is expressed by external stimuli and plays a physiologically important role as a self-defense substance that destroys microbes or tumor cells invading from the outside. However, excessive production of NO acts as a factor inducing inflammation of the cells, which causes various chronic inflammatory diseases. The inflammatory response is induced when tissue damage or infection is caused by free radicals in the body. Typically, macrophages react to produce cytokines, and the expression of inducible nitric oxide synthase (iNOS) Since NO is produced, anti-inflammatory activity can be evaluated by inhibiting the expression of iNOS. LPS induces oxidative stress and stimulates immune cells as a cell wall material of gram negative bacteria, thereby increasing NO production.
열수추출물인 경우 각각의 추출물을 125~2,000 ㎍/mL로 처리하였을 때 농도가 증가할수록 세포독성이 관찰된 반면에서 NO 생성에 미치는 영향은 나타나지 않아 모든 농도에서 NO 생성 저해효과는 관찰되지 않았다. 이와 반면에 에탄올 추출물의 농도를 125~2,000 ㎍/mL로 처리하였을 때 1,000 ㎍/mL 이하의 농도에서는 세포독성이 관찰되지 않았으나 2,000 ㎍/mL의 고농도에서는 브로콜리 첨가, 양배추 첨가, 당근 첨가군에서 세포독성이 관찰되었다. 세포독성이 나타나지 않은 농도에서 에탄올 추출물의 NO 생성 억제 활성은 농도 의존적으로 증가하는 경향을 나타내었는데, 1,000 ㎍/mL 농도에서 브로콜리 첨가 제품에서 47.0%, 양배추 첨가제품 47.9% 및 당근 첨가제품 46.5%의 NO 억제 효과를 나타내었다. 감귤이 첨가된 실시예 5는 농도 2,000 ㎍/mL에서 48.3%의 NO 생성 억제효과가 나타났다.
In the case of hydrothermal extract, cytotoxicity was observed as the concentration of each extract increased from 125 to 2,000 ㎍ / mL, but no effect on NO production was observed. On the other hand, when the concentration of ethanol extract was treated with 125 ~ 2,000 ㎍ / mL, cytotoxicity was not observed at the concentration of 1,000 ㎍ / mL. However, at the high concentration of 2,000 ㎍ / mL, broccoli, cabbage, Toxicity was observed. At the concentration of 1,000 ㎍ / mL, 47.0% of broccoli added, 47.9% of cabbage added and 46.5% of carrot added NO inhibitory effect. Example 5 in which citrus was added showed an inhibitory effect on NO production of 48.3% at a concentration of 2,000 ㎍ / mL.
1) 감귤 첨가1) Adding Citrus
도 1에 나타낸 바와 같이, 열수추출물은 75.1%~88.5%의 세포 생존율을 보였으며 열수 추출물의 농도가 증가할수록 세포 생존율은 감소하는 경향을 보였다. 한편 열수 추출물의 NO 생성에 미치는 영향을 조사한 결과 처리된 모든 농도에서 NO 생성 저해 효과는 관찰되지 않았다. 한편, 에탄올추출물은 125~1,000 ㎍/ML 농도 범위에서는 100% 이상의 세포 생존율을 보였으나, 2,000 ㎍/mL 농도에서는 63.9%의 세포 생존율을 보여 열수 추출물과 동일하게 세포독성이 있는 것으로 평가되었다. 세포 독성이 나타나지 않은 농도(125~1,000 ㎍/mL)에서 에탄올 추출물의 NO생성에 미치는 영향을 조사한 결과, 추출물의 농도가 증가할수록 NO 생성 억제에 영향을 주는 것으로 나타났으며 추출물 농도 2,000 ㎍/mL에서 48.3%의 NO 생성 억제를 나타내었다.
As shown in FIG. 1, the cell survival rate of the hot-water extract was 75.1% ~ 88.5%, and the cell survival rate tended to decrease with increasing hot-water extract concentration. On the other hand, the effect of hydrothermal extract on NO production was not observed at all concentrations. On the other hand, the ethanol extract showed cell viability of 100% or more at the concentration range of 125 ~ 1,000 ㎍ / mL, but cell viability was 63.9% at the concentration of 2,000 ㎍ / mL. The effect of ethanol extract on the NO production was investigated in the absence of cytotoxicity (125 ~ 1,000 ㎍ / mL). As the concentration of extract increased, And 48.3%, respectively.
2) 브로콜리 첨가2) Adding broccoli
도 2에 나타낸 바와 같이, 열수추출물은 125~1,000 ㎍/mL 농도 범위에서는 100% 이상의 세포 생존율을 보였으나, 2,000 ㎍/mL 농도에서는 89.6%의 세포 생존율을 보여 세포독성이 있는 것으로 평가되었다. 열수 추출물의 NO 생성에 미치는 영향을 조사한 결과 처리된 모든 농도에서 NO 생성 저해 효과는 관찰되지 않았다. 한편, 에탄올추출물은 125~1,000 ㎍/mL 농도 범위에서는 100% 이상의 세포 생존율을 보였으나, 2,000 ㎍/mL 농도에서는 63.9%의 세포 생존율을 보여 열수 추출물과 동일하게 세포독성이 있는 것으로 평가되었다. 세포 독성이 나타나지 않은 농도(125~1,000 ㎍/mL)에서 에탄올 추출물의 NO생성에 미치는 영향을 조사한 결과, 추출물의 농도가 증가할수록 NO 생성 억제에 영향을 주는 것으로 나타났으며 추출물 농도 1,000 ㎍/mL 농도에서 47.9%의 NO 생성 억제를 나타내었다.
As shown in FIG. 2, the cell survival rate of the hot-water extract was 100% or more at the concentration range of 125 to 1,000 ㎍ / mL, but the cell survival rate was 89.6% at the concentration of 2,000 ㎍ / mL. The effect of hot water extract on NO production was not observed at all concentrations. On the other hand, the ethanol extract showed cell viability of 100% or more at the concentration range of 125 ~ 1,000 ㎍ / mL, but cell viability was 63.9% at the concentration of 2,000 ㎍ / mL. The effect of ethanol extract on the NO production was investigated in the absence of cytotoxicity (125 ~ 1,000 ㎍ / mL). As the concentration of extract increased, the NO production was inhibited. The extract concentration was 1,000 ㎍ / mL The inhibition of NO production was 47.9%.
3) 양배추 첨가3) Cabbage addition
도 4에 나타낸 바와 같이, 열수추출물은 125~1,000 ㎍/mL 농도 범위에서는 100% 이상의 세포 생존율을 보였으나, 2,000 ㎍/mL 농도에서는 83.6%의 세포 생존율을 보여 세포독성이 있는 것으로 평가되었다. 열수 추출물의 NO 생성에 미치는 영향을 조사한 결과 처리된 모든 농도에서 NO 생성 저해 효과는 관찰되지 않았다.As shown in FIG. 4, the cell survival rate of the hot-water extract was 100% or more at the concentration range of 125 to 1,000 ㎍ / mL, but the cell survival rate was 83.6% at the concentration of 2,000 ㎍ / mL. The effect of hot water extract on NO production was not observed at all concentrations.
한편, 에탄올추출물은 125~1,000 ㎍/mL 농도 범위에서는 100% 이상의 세포 생존율을 보였으나, 2,000 ㎍/mL 농도에서는 74.3%의 세포 생존율을 보여 열수 추출물과 동일하게 세포독성이 있는 것으로 평가되었다. 세포 독성이 나타나지 않은 농도(125~1,000 ㎍/mL)에서 에탄올 추출물의 NO생성에 미치는 영향을 조사한 결과, 추출물의 농도가 증가할수록 NO 생성 억제에 영향을 주는 것으로 나타났으며 추출물 농도 1,000 ㎍/mL 농도에서 46.5%의 NO 생성 억제를 나타내었다.
On the other hand, the ethanol extract showed cell viability of more than 100% in the concentration range of 125 ~ 1,000 ㎍ / mL, but showed cell viability of 74.3% at the concentration of 2,000 ㎍ / mL. The effect of ethanol extract on the NO production was investigated in the absence of cytotoxicity (125 ~ 1,000 ㎍ / mL). As the concentration of extract increased, the NO production was inhibited. The extract concentration was 1,000 ㎍ / mL And inhibited the production of NO by 46.5%.
4) 당근 첨가4) Adding carrots
도 4에 나타낸 바와 같이, 열수추출물은 125~1,000 ㎍/mL 농도 범위에서는 100% 이상의 세포 생존율을 보였으나, 2,000 ㎍/mL 농도에서는 89.4%의 세포 생존율을 보여 세포독성이 있는 것으로 평가되었다. 열수 추출물의 NO 생성에 미치는 영향을 조사한 결과 처리된 모든 농도에서 NO 생성 저해 효과는 관찰되지 않았다. 한편, 에탄올추출물은 125~1,000 ㎍/mL 농도 범위에서는 100% 이상의 세포 생존율을 보였으나, 2,000 ㎍/mL 농도에서는 76.9%의 세포 생존율을 보여 열수 추출물과 동일하게 세포독성이 있는 것으로 평가되었다. 세포 독성이 나타나지 않은 농도(125~1,000 ㎍/mL)에서 에탄올 추출물의 NO생성에 미치는 영향을 조사한 결과, 추출물의 농도가 증가할수록 NO 생성 억제에 영향을 주는 것으로 나타났으며 추출물 농도 1,000 ㎍/mL 농도에서 46.5%의 NO 생성 억제를 나타내었다.
As shown in FIG. 4, the cell survival rate of the hot-water extract was 100% or more at the concentration range of 125 to 1,000 ㎍ / mL, but the cell survival rate was 89.4% at the concentration of 2,000 ㎍ / mL. The effect of hot water extract on NO production was not observed at all concentrations. The ethanol extracts showed cell viability of more than 100% at the concentration range of 125 ~ 1,000 ㎍ / mL, but cell viability was 76.9% at the concentration of 2,000 ㎍ / mL. The effect of ethanol extract on the NO production was investigated in the absence of cytotoxicity (125 ~ 1,000 ㎍ / mL). As the concentration of extract increased, the NO production was inhibited. The extract concentration was 1,000 ㎍ / mL And inhibited the production of NO by 46.5%.
시험예Test Example 4. 관능 검사 4. Sensory evaluation
실시예 1 내지 5 및 비교예 1 내지 3에서 제조된 현맥 과립을 전문패널 20명에게 시식하게 한 후 9점 척도법(정도가 클수록 9점에 가까움)으로 관능검사를 실시하여 평균값 구하였으며, 이를 하기 표 7에 나타내었다.The sensory evaluation was carried out on a panel of 20 experts on the basis of the sensory granules prepared in Examples 1 to 5 and Comparative Examples 1 to 3, and then a sensory test was carried out using a 9-point scale method Table 7 shows the results.
-고소한맛 및 단맛: 1점= 매우 약하다, 9점= 매우 강하다 - Sweet taste and sweetness: 1 point = very weak, 9 point = very strong
-식감 및 종합적 기호도: 1점= 매우 나쁘다, 9점= 매우 좋다- texture and general preference: 1 point = very bad, 9 points = very good
상기 표 7에 나타낸 바와 같이, 본 발명의 실시예 1 내지 5에 따른 현맥 과립은 비교예 1 내지 3에 비해 고소한 맛과 단맛이 강하며, 식감이 부드러워 기호도가 우수한 것으로 확인되었다. As shown in Table 7, it was confirmed that the rhizome granules according to Examples 1 to 5 of the present invention are stronger in flavor and sweetness than those of Comparative Examples 1 to 3, and have a pleasant texture and excellent taste.
반면, 비교예 1과 2는 단맛과 식감에서 좋지 못한 평가를 받았으며, 과채 농축액 대신 물을 사용한 비교예 3은 식감이 현저히 떨어지는 것으로 확인되었다.
On the other hand, Comparative Examples 1 and 2 were rated poorly in sweetness and texture, and Comparative Example 3 using water in place of the fruit juice concentrate was found to have significantly reduced texture.
Claims (11)
(b) 상기 발아된 현맥을 덱스트린화하는 단계;
(c) 진공 상에서 상기 덱스트린화된 현맥을 유산균으로 발효시키는 단계;
(d) 상기 유산균으로 발효된 현맥을 분말화하는 단계; 및
(e) 상기 분말화된 현맥에 과채 농축액을 스프레이 형태로 분사하면서 유동층 건조(fluid bed crying) 방식으로 과립을 생성시키는 단계;를 포함하는 현맥 과립 제조방법.(a) germinating an unspotted spot;
(b) dextrinizing the germinated rhizome;
(c) fermenting said dextrinized rhizome with lactic acid bacteria on a vacuum;
(d) pulverizing the rhizome fermented with the lactic acid bacteria; And
(e) forming a granule by a fluid bed crying method while spraying a concentrated liquid of the fruit and vegetable in the powdered rhombus.
상기 (a) 단계는 현맥 100 중량% 중에서 85 내지 90 중량%만을 발아시키는 것을 특징으로 하는 현맥 과립 제조방법.The method according to claim 1,
Wherein the step (a) comprises germinating only 85 to 90% by weight of 100% by weight of rhizome.
상기 (a) 단계는 발아된 현맥 유근의 시원체인 백체의 길이가 0.05 이상 내지 1 mm 미만인 것을 특징으로 하는 현맥 과립 제조방법.The method according to claim 1,
Wherein the step (a) is performed such that the length of the germ, which is a germinated rootstock root, is less than 0.05 to less than 1 mm.
상기 (b) 단계는 덱스트린화 하기 전에 발아 현맥을 춘화처리하는 단계를 더 포함하는 것을 특징으로 하는 현맥 과립 제조방법.The method according to claim 1,
Wherein the step (b) further comprises the step of subjecting the germination axis to a sexualization process before dextrinization.
상기 (c) 단계는 현맥 10 중량부에 대하여 미강 3 내지 15 중량부를 혼합하여 유산균으로 발효시키는 것을 특징으로 하는 현맥 과립 제조방법.The method according to claim 1,
Wherein the step (c) comprises mixing 3 to 15 parts by weight of rice bran with respect to 10 parts by weight of a row of beans, followed by fermentation with lactic acid bacteria.
상기 과채 농축액은 과일 또는 채소를 착즙하여 농축한 농축액; 또는 과일 또는 채소를 세포벽 분해효소로 효소처리한 후 착즙하여 농축한 농축액인 것을 특징으로 하는 현맥 과립 제조방법. The method according to claim 1,
Wherein the fruit and vegetable concentrate is a concentrated fruit and vegetable concentrate; Or a concentrate obtained by enzymatic treatment of fruit or vegetable with a cell wall degrading enzyme, followed by juice concentrating and concentrating.
상기 과채는 감귤, 브로콜리, 양배추 및 당근 중에서 선택되는 것을 특징으로 하는 현맥 과립 제조방법. 8. The method of claim 7,
Wherein the fruit is selected from citrus, broccoli, cabbage and carrots.
상기 (d) 단계는 분말화하기 전에 유산균으로 발효된 현맥에 과채 효소분해물을 분사한 뒤 1 내지 6시간 동안 숙성시키는 단계를 더 포함하는 것을 특징으로 하는 현맥 과립 제조방법.The method according to claim 1,
Wherein the step (d) further comprises the step of spraying the enzyme hydrolyzate to fermented lactic acid bacteria before powdering and then aging for 1 to 6 hours.
상기 과채 효소분해물은 감귤, 브로콜리, 양배추 및 당근 중에서 선택되는 과채를 베타-글루카나아제(β-glucanase), 헤미셀룰라아제(hemicellulase), 셀룰라아제(cellulase), 자일란나아제(xylanase), 펙티나아제(pectinase) 및 아라비나아제(arabinase) 중에서 선택되는 1종 또는 2종 이상의 세포벽 분해효소로 효소분해한 다음 효소를 실활시키고, 착즙하여 제조된 것을 특징으로 하는 현맥 과립 제조방법.9. The method of claim 8,
The enzyme hydrolyzate of the present invention is an enzyme hydrolyzate selected from the group consisting of citrus, broccoli, cabbage and carrots as beta-glucanase, hemicellulase, cellulase, xylanase and pectinase pectinase and arabinase, and then enzymatically decomposing the enzyme with one or two or more kinds of cell wall degrading enzymes selected from the group consisting of pectinase, pectinase and arabinase.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160164609A KR101926684B1 (en) | 2016-12-05 | 2016-12-05 | Manufacturing method of husked barley granules |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160164609A KR101926684B1 (en) | 2016-12-05 | 2016-12-05 | Manufacturing method of husked barley granules |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20180064222A true KR20180064222A (en) | 2018-06-14 |
KR101926684B1 KR101926684B1 (en) | 2018-12-07 |
Family
ID=62629376
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020160164609A KR101926684B1 (en) | 2016-12-05 | 2016-12-05 | Manufacturing method of husked barley granules |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101926684B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109007818A (en) * | 2018-06-21 | 2018-12-18 | 江苏省农业科学院 | The preparation method and its purposes in terms of cellular anti-oxidant of a kind of wheat extract |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR950024677A (en) | 1994-02-24 | 1995-09-15 | 서중일 | Method of Making Barley Young Leaf Powder (Granules) |
JP3769274B2 (en) * | 2003-08-29 | 2006-04-19 | 日本製粉株式会社 | Green leaf granule and method for producing green leaf granule |
KR20060100477A (en) * | 2003-12-11 | 2006-09-20 | 삿뽀로 비루 가부시키가이샤 | Processed wheat product containing functional components in elevated amounts and processing method therefor |
KR100844080B1 (en) | 2007-03-28 | 2008-07-04 | 한국식품연구원 | Granulated sunshik and process for preparing the same |
KR20120039374A (en) * | 2010-10-15 | 2012-04-25 | 이규길 | Method for preparing raw material for functional food |
KR20150034909A (en) * | 2013-09-27 | 2015-04-06 | 농업회사법인 아람농장(주) | Granule-type convenient food using the concentrate of enzyme extract from fruits or vegetables and manufacturing method thereof |
KR101570190B1 (en) * | 2013-11-22 | 2015-11-18 | 농업회사법인 제주홍암가 주식회사 | Manufacturing method of pressed barley for rice boiling using husked barley and for pressed barley rice boiling manufactured thereby |
KR20160100620A (en) | 2015-02-16 | 2016-08-24 | 주식회사 영일이엔에프 | Manufacturing method of barley extract granule |
-
2016
- 2016-12-05 KR KR1020160164609A patent/KR101926684B1/en active IP Right Grant
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR950024677A (en) | 1994-02-24 | 1995-09-15 | 서중일 | Method of Making Barley Young Leaf Powder (Granules) |
JP3769274B2 (en) * | 2003-08-29 | 2006-04-19 | 日本製粉株式会社 | Green leaf granule and method for producing green leaf granule |
KR20060100477A (en) * | 2003-12-11 | 2006-09-20 | 삿뽀로 비루 가부시키가이샤 | Processed wheat product containing functional components in elevated amounts and processing method therefor |
KR100844080B1 (en) | 2007-03-28 | 2008-07-04 | 한국식품연구원 | Granulated sunshik and process for preparing the same |
KR20120039374A (en) * | 2010-10-15 | 2012-04-25 | 이규길 | Method for preparing raw material for functional food |
KR20150034909A (en) * | 2013-09-27 | 2015-04-06 | 농업회사법인 아람농장(주) | Granule-type convenient food using the concentrate of enzyme extract from fruits or vegetables and manufacturing method thereof |
KR101570190B1 (en) * | 2013-11-22 | 2015-11-18 | 농업회사법인 제주홍암가 주식회사 | Manufacturing method of pressed barley for rice boiling using husked barley and for pressed barley rice boiling manufactured thereby |
KR20160100620A (en) | 2015-02-16 | 2016-08-24 | 주식회사 영일이엔에프 | Manufacturing method of barley extract granule |
Non-Patent Citations (1)
Title |
---|
일본 특허공보 특허 제 3769274호(2006.04.19.) 1부. * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109007818A (en) * | 2018-06-21 | 2018-12-18 | 江苏省农业科学院 | The preparation method and its purposes in terms of cellular anti-oxidant of a kind of wheat extract |
Also Published As
Publication number | Publication date |
---|---|
KR101926684B1 (en) | 2018-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhang et al. | Phytochemical constituents and biological activities of longan (Dimocarpus longan Lour.) fruit: A review | |
EP2322042B1 (en) | Method for preparing raw material for functional foods from barley or wheat seeds | |
CN102648751B (en) | Engineering rice with functions of alleviating hangover and protecting liver and preparation method of engineering rice | |
Ren et al. | Nutrient composition, functional activity and industrial applications of quinoa (Chenopodium quinoa Willd.) | |
KR20120107557A (en) | Rice bran fermentation extracts with chlorophyll and the manufacturing method thereof | |
CN103621884B (en) | Composite nutritional rice and the manufacture craft thereof of multiple nutrients can be provided | |
KR20110048236A (en) | Compositions for prevention and improvement of cancer containing the extracts of native plants as an active ingredient | |
KR101247935B1 (en) | Method for Preparing Raw Material for Functional Food | |
CN105394504A (en) | Hypoglycemic germinated brown rice juice and preparation method thereof | |
US9161495B2 (en) | Method for preparing raw material for functional foods from barley or wheat seeds | |
Shahidi et al. | Phenolic compounds in cereal grains and effects of processing on their composition and bioactivities: A review | |
JPH08266248A (en) | Composition of dehydrated powder green bean sprout and vegetable fiber that are useful as food supplies in health care | |
JP2018102202A (en) | Green leaf powder and composition | |
KR101926684B1 (en) | Manufacturing method of husked barley granules | |
Shahrajabian et al. | Potential roles of longan as a natural remedy with tremendous nutraceutical values | |
KR102002576B1 (en) | Functional Germinated Soybean Meju Comprising Extract of Polygala tenuifolia and Manufactuaring Method thereof | |
CN108308535A (en) | It is a kind of that there are the natto health-oriented products and preparation method thereof for improving brain neuroblastoma function | |
Saurabh et al. | Antinutritional Factors in Cereals | |
Jide et al. | Adzuki (Vigna angularis) beans as food: Chemical composition, nutrition and quality identities | |
KR102563199B1 (en) | Mushroom scorched rice manufacturing method using cordyceps sinensis and mushroom scorched rice prepared thereby | |
KR20190118057A (en) | Manufacturing method of brown rice-seaweed composition fermented aspergillus | |
Popović et al. | Medicinal properties of buckwheat products and honey in compliance with food safety regulatory requirements | |
KR20180129579A (en) | Onion Coat composition Using An Enzyme With Stevia Extract And Method thereof | |
Bvenura et al. | Back to the Future–The Prospects of African Indigenous Crops as Future Foods | |
Gondi et al. | Bioactive molecules and health benefits of mango peel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |